Venetoclax-Enhanced Reduced Intensity Conditioning

A Phase II Trial of Venetoclax-Enhanced Reduced Intensity HLA-Mismatched Allogeneic Transplant for Ultra-High-Risk Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)

More Information

Trial Status
Withdrawn
Trial Phase
Phase 2
Sponsors
Northside Hospital
Tags
Allogeneic Stem Cell Transplant, BCL-2 Inhibitor
Trial Type
Treatment
Last Update
2 months ago
SparkCures ID
1868
NCT Identifier
NCT06337331

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print Report

Print this trial to share with your doctor.

(888) 803-1766

We can help answer any questions and connect you (or your patient) with the study team.

Schedule Call

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.